Recent News

• 03.25.2025 - X4 Pharmaceuticals Fourth Quarter 2024 Financial Results
• 03.25.2025 - X4 Pharmaceuticals Fourth Quarter 2024 Financial Results
• 03.11.2025 - X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025
• 03.11.2025 - X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025
• 02.19.2025 - X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries
• 02.19.2025 - X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries
• 02.06.2025 - X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia
• 02.06.2025 - X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia
• 02.03.2025 - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 02.03.2025 - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 03.03.2025 - 8-K Current report
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.06.2025 - 8-K Current report
• 02.06.2025 - EX-99.1 EX-99.1